New York, USA – July 11, 2020 – ADC refers to a kind of novel therapeutic biotechnological drug and a potent drug targeting cancer, which is made up of monoclonal antibody and high toxic small molecule poison (ADC toxins). Creative Biolabs provides qualified ADC toxin products that are developed with the help of the “DrugLnk” service platform, and well prepared for the clients who are working on developing specific ADCs. In spite of the COVID-19 epidemic, scientists at Creative Biolabs devote as they can to ensure instant delivery to accelerate customers’ research process.
There are highly potent toxins and toxin derivatives targeting various cellular approaches available at Creative Biolabs: microtubule assemble and dynamics (microtubule toxins), DNA biochemistry and structure (DNA toxins), and gene transcription (transcription toxins). The ADC toxins specifically targeting crucial intracellular pathways to cause cell death include common auristatins, maytansinoids, calicheamicins and more innovative toxins such as amatoxins.
* Auristatin E (ADC-P-004): a cytotoxic tubulin modifier with potent and selective antitumor activity
* Englerin A (ADC-P-086): a potent and selective activator of TRPC4 and TRPC5 calcium channels
* DM1 (ADC-P-033): a kind of maytansinoid that shares similar structure with ifamycin, geldanamycin, and ansatrienin
* Fumagillin (ADC-P-091): a methionine aminopeptidase-2 (MetAP-2) that inhibits endothelial cell proliferation and angiogenesis
Considering that the clients with diversified research purposes may not find satisfactory in the products catalog, Creative Biolabs is offering DrugLnk™ custom synthesis solutions to handle requests on ADC payloads, ADC linkers, and drug-linker complexes construction, which ensure to deliver the most satisfactory linker complexes, ready for research use.
ADC toxin product is only a part of solutions at Creative Biolabs who has comprehensive products and custom services associated with the development of antibody-drug conjugate (ADC). The product list consists of drug link products, anti-Ab ADCs, anti-drug Abs, and customized products upon requests, which are applicable for proof-of-concept, target validation, and control to offer comparison in efficacy for new ADC development projects. The service portfolio covers the development of ADC, antibody-antibiotic conjugate (AAC), antibody-enzyme conjugates or cancer therapy, antibody-based probes, etc.
More details can be found at https://www.creative-biolabs.com/adc.
About Creative Biolabs
Creative Biolabs is a service provider in the field of biotechnology, who is specialized in antibody discovery and manufacturing. Since its establishment in 2004, it has gone through over a decade of steady operation and has successfully expanded its business throughout the world. Except for the headquarter in New York in the United States, Creative Biolabs recently set up its new office in Europe, with the aim to better accommodate the increasing inquiries on antibody technologies from global clients.
Based upon the high-end technology platforms and with the support of experienced scientists, Creative Biolabs can assist with the entire pipeline of ADC development that starts from ADC formulation to clinical tests.